Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
BioLineRx Ltd. (BLRX.TA)
Modi'in, IL
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +15.38% | +25.00% | +0.00% | -16.67% | -6.25% | -28.57% | -95.80% | -97.64% | -99.59% | -99.97% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2025-04 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-95.6% Q1'26: +87.1% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+93.5% ★ Q1'26: -134.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-831.4% Q1'26: -479.2% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-871.8% Q1'26: -490.1% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-88.2% Q1'26: -74.5% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+105.8% Q1'26: +49.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.96× Q1'26: -1.01× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 49.5K (-100.0%)
|
—
est: 103.30M (-100.0%)
|
4.80M
est: 150.9K (+3,081.8%)
|
28.94M
est: 24.91M (+16.2%)
|
1.28M
est: 1.46M (-12.3%)
|
1.35M
1.35M – 1.36M
-7.2% YoY
|
1.82M
1.76M – 1.88M
+34.4% YoY
|
3.41M
3.34M – 3.48M
+87.4% YoY
|
6.69M
6.56M – 6.83M
+96.6% YoY
|
15.62M
15.29M – 15.94M
+133.3% YoY
|
| EBITDA |
-26.85M
est: 1.3K (-2,002,411.7%)
|
-27.17M
est: 2.80M (-1,071.4%)
|
-57.09M
est: 4.1K (-1,397,896.3%)
|
3.92M
est: 674.5K (+480.8%)
|
-10.57M
est: 39.5K (-26,891.5%)
|
36.6K
36.5K – 36.8K
-7.2% YoY
|
49.2K
47.6K – 50.8K
+34.4% YoY
|
92.2K
90.3K – 94.1K
+87.4% YoY
|
181.3K
177.5K – 185.0K
+96.6% YoY
|
422.9K
414.1K – 431.6K
+133.3% YoY
|
| EBIT |
-25.61M
est: -50.00 (-51,209,900.0%)
|
-28.11M
est: -104.9K (-26,687.4%)
|
-58.47M
est: -153.00 (-38,215,586.3%)
|
-147.0K
est: -25.3K (-480.8%)
|
-11.14M
est: -1.5K (-752,290.3%)
|
-1.4K
-1.4K – -1.4K
+7.2% YoY
|
-1.8K
-1.9K – -1.8K
-34.5% YoY
|
-3.5K
-3.5K – -3.4K
-87.4% YoY
|
-6.8K
-6.9K – -6.7K
-96.6% YoY
|
-15.9K
-16.2K – -15.5K
-133.3% YoY
|
| Net Income |
-22.96M
est: -616.86M (+96.3%)
|
-26.81M
est: -360.74M (+92.6%)
|
-60.61M
est: -162.79M (+62.8%)
|
-9.22M
est: -12.13M (+24.0%)
|
-1.27M
est: -1.40M (+9.0%)
|
-2.05M
-2.10M – -1.99M
-46.4% YoY
|
-1.24M
-1.28M – -1.21M
+39.1% YoY
|
-2.53M
-2.60M – -2.46M
-103.0% YoY
|
-2.34M
-2.41M – -2.28M
+7.3% YoY
|
-1.30M
-1.34M – -1.27M
+44.5% YoY
|
| SGA |
5.77M
est: 120.2K (+4,699.0%)
|
4.60M
est: 250.67M (-98.2%)
|
31.23M
est: 366.1K (+8,431.2%)
|
28.54M
est: 60.45M (-52.8%)
|
3.37M
est: 3.54M (-4.6%)
|
3.28M
3.27M – 3.29M
-7.2% YoY
|
4.41M
4.27M – 4.56M
+34.4% YoY
|
8.26M
8.09M – 8.44M
+87.4% YoY
|
16.25M
15.91M – 16.58M
+96.6% YoY
|
37.90M
37.12M – 38.68M
+133.3% YoY
|
| EPS |
-0.21
est: -0.25 (+16.1%)
|
-0.18
est: -0.15 (-23.0%)
|
-0.06
est: -0.07 (+4.7%)
|
-0.01
est: 0.00 (-56.5%)
|
0.00
est: 0.00 (+11.8%)
|
0.00
0.00 – 0.00
-46.4% YoY
|
0.00
0.00 – 0.00
+39.1% YoY
|
0.00
0.00 – 0.00
-103.0% YoY
|
0.00
0.00 – 0.00
+7.3% YoY
|
0.00
0.00 – 0.00
+44.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-26 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-25 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Philip A. Serlin | Chief Executive Officer | 560.0K | male |
| Ella Sorani | Chief Development Officer | 386.0K | — |
| Mali Zeevi | Chief Financial Officer | 348.0K | female |
| John Lacey | Head of Corporation Communications & Investor Relations | — | male |
| Raziel Fried | Treasurer & Budgetary Control Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BLRX.TA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
